August 13, 2019

Evonik is sticking to its full-year outlook despite an increasingly gloomy economic environment, the company said at the start of August.

Evonik expects sales and adjusted EBITDA from continued operations to remain at least stable compared with last year. In 2018, it generated - not including the divested Methacrylates business - sales of €13.3 billion (US$15 billion) and adjusted EBITDA of €2.15 billion (US$2.4 billion).

In the second quarter of this year sales declined 3% to €3.31 billion (US$3.7 billion) compared with the prior-year quarter. While sales volumes fell because of the weaker economy, Evonik was able to keep prices largely stable. Adjusted EBITDA fell 8% to €566 million (US$634.4 million) in the quarter. In comparison to the first quarter of 2019, all three of the company's chemical segments were able to improve their earnings. For the second half of the year Evonik expects a continued solid development.

"We are on track and confirm our forecast," said Christian Kullmann, chairman of Evonik's executive board. "The cooling of world trade and an increasing weakness in major industries isn't making it easier. Still, we are confident for the remainder of the year."

In the first half, free cash flow reached €95 million (US$106.5 million). That is more than double the amount in the first half of 2018 (€46 million). So Evonik is on track to meet its target for a significantly higher free cash flow for the full year.

"Strategically we have taken a big step forward with focusing our portfolio on specialty chemicals," said Kullmann. "We invest in areas with stable and attractive growth perspectives and divest cyclical businesses when the time is right. That makes Evonik less exposed to economic cycles."

As well as the sale of the Methacrylates business to Advent International, the company has reached another milestone. On July 10, Veramaris, a joint venture between Evonik and Dutch company DSM, officially opened its production plant for omega-3 fatty acids needed for healthy salmon farming. A tangible earnings contribution from the project, which contributes to long-term sustainable animal nutrition and helps conserve biodiversity in the oceans, is expected from next year.

For Evonik's Nutrition and Care segment, second-quarter sales decreased 5% to €1.31 billion (US$1.5 billion) at the segment. Demand for essential amino acids for animal nutrition remained high while selling prices were lower than the prior-year quarter.

Adjusted EBITDA at the segment dropped 14% to €190 million (US$213 million) on lower prices as well as ramp-up costs for the new methionine facility in Singapore.

- Evonik